A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Clinical trial NCT04596995 · TERMINATED
Trial details
- NCT number
- NCT04596995
- Sponsor
- UCB Biopharma SRL
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-06
- Primary completion
- 2022-12-21
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.